JG
IBB icon

Jefferies Group’s iShares Biotechnology ETF IBB Stock Holding History

Jefferies Group’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$22.5M Buy
192,500
+40,500
+27% +$5.03M 0.19% 80
2022
Q2 		$17.9M Sell
152,000
-117,700
-44% -$14M 0.15% 102
2022
Q1 		$35.1M Buy
269,700
+187,900
+230% +$24.5M 0.22% 66
2021
Q4 		$12.5M Sell
81,800
-95,400
-54% -$14.8M 0.07% 223
2021
Q3 		$28.6M Sell
177,200
-10,900
-6% -$1.83M 0.21% 75
2021
Q2 		$30.8M Buy
188,100
+51,700
+38% +$7.96M 0.19% 73
2021
Q1 		$20.5M Buy
136,400
+900
+0.7% +$143K 0.18% 89
2020
Q4 		$20.5M Sell
135,500
-361,500
-73% -$51.7M 0.16% 102
2020
Q3 		$67.3M Sell
497,000
-123,900
-20% -$16.8M 0.74% 14
2020
Q2 		$84.9K Sell
620,900
-109,700
-15% -$14M 1% 12
2020
Q1 		$78.7M Buy
730,600
+478,900
+190% +$55.1M 0.87% 8
2019
Q4 		$30.3M Sell
251,700
-158,100
-39% -$17.6M 0.23% 64
2019
Q3 		$40.8M Buy
409,800
+77,700
+23% +$8.13M 0.32% 36
2019
Q2 		$36.2M Buy
332,100
+90,400
+37% +$9.62M 0.26% 49
2019
Q1 		$27M Buy
241,700
+192,300
+389% +$21.1M 0.22% 51
2018
Q4 		$4.76M Buy
+49,400
New +$5.24M 0.04% 437
2018
Q2 		– Sell
-220,900
Closed -$23.6M – 2473
2018
Q1 		$23.6M Buy
220,900
+220,600
+73,533% +$24.5M 0.13% 100
2017
Q4 		$32K Hold
300
– – ﹤0.01% 2405
2017
Q3 		$33K Buy
+300
New +$32.1K ﹤0.01% 2236
2017
Q2 		– Sell
-300
Closed -$29K – 2358
2017
Q1 		$29K Sell
300
-88,500
-100% -$8.47M ﹤0.01% 2224
2016
Q4 		$7.86M Sell
88,800
-30,900
-26% -$2.81M 0.04% 413
2016
Q3 		$11.5M Buy
+119,700
New +$11.4M 0.06% 268
2015
Q2 		– Sell
-13,200
Closed -$1.51M – 3389
2015
Q1 		$1.51M Sell
13,200
-45,900
-78% -$5.06M 0.01% 869
2014
Q4 		$5.98M Sell
59,100
-53,700
-48% -$5.22M 0.04% 373
2014
Q3 		$10.3M Buy
+112,800
New +$9.9M 0.07% 237

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Jefferies Group's IBB Position: Q3 2022 in Review

Jefferies Group increased its iShares Biotechnology ETF (IBB) stake by 151,333% in Q3 2022, buying an estimated $21.2M and bringing the position to 171,119 shares worth $20M. The position accounts for 0.17% of the portfolio, ranked #96.

Jefferies Group first reported a position in IBB in Q2 2014 and has held it in 30 quarters since. The position peaked at $38.7M in Q1 2018. 829 funds tracked by Wall St. Rank hold IBB as of Q3 2022.

  • Jefferies Group held 171,119 shares of iShares Biotechnology ETF worth $20M as of Q3 2022.
  • Jefferies Group bought 171,006 iShares Biotechnology ETF shares in Q3 2022, an estimated $21.2M.
  • iShares Biotechnology ETF made up 0.17% of Jefferies Group's portfolio in Q3 2022, its #96 holding.
  • Jefferies Group first reported a position in iShares Biotechnology ETF in Q2 2014 and has held it in 30 quarters since.
  • Jefferies Group's iShares Biotechnology ETF position peaked at $38.7M in Q1 2018.
  • 829 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.